QTI News & Events

Reports Q1 revenue $6.5M vs. $2.8M last year. "We continued to execute during the first quarter, making meaningful progress across commercialization, regulatory execution, and clinical validation," said Dr. Raluca Dinu, CEO. "During the quarter, we shipped 13 QT Breast Acoustic CT systems, in line with our commercial distribution commitments, secured a dedicated Category III CPT code for our technology that becomes effective as of January 2027, and received FDA 510(k) clearance for enhancements that improve visualization of posterior breast tissue. Recently, the maturity date of our senior secured term loan with our lender was extended by two years from March 31, 2027 to March 31, 2029. This extension provides the Company with additional financial flexibility as we continue executing on our commercial, clinical, and strategic growth initiatives. "Importantly, we also expanded internationally with regulatory clearance in the United Arab Emirates, supporting a previously established multiyear commercial agreement in the region. At the same time, we advanced our technology platform through the launch of the QT Imaging-Olea Viewer and released a meaningful software improvement focused on reflection image quality, workflow, and quantitative analysis. Our clinical strategy continues to gain momentum through investigator studies at leading institutions that demonstrate strong concordance between QTscan and MRI. We believe QTscan is uniquely positioned as a radiation-free, compression-free, true 3D breast-imaging platform capable of providing quantitative information meant to improve clinical decision making, particularly for women with dense breasts. We remain focused on disciplined execution as we expand adoption of the platform globally," she added.

The Company reaffirms guidance for 2026 revenue to be approximately $39 million, reflecting scanner shipments in the U.S. and world-wide, and initial revenue from the QT Imaging Cloud Platform. These expectations are in accordance with the MOQs per its Amended Distribution Agreement with its U.S. strategic business and distribution partner, NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, as well as its new distribution partners in the Gulf region, Gulf Medical and Al Naghi Medical.

QT Imaging Holdings announced that Barry Roseman, MD, FACS, is serving as a Senior Medical Advisor to the company. Dr. Roseman's engagement includes clinical implementation of the QT Imaging technology in a busy breast diagnostic and screening center. This installation is expected to support physician training, workflow integration, patient access, and ongoing collection of real-world clinical, operational, financial, patient, and provider experiences. "Dr. Roseman's involvement with QT Imaging is substantially more than a traditional advisory role, and we are honored to enter into this new relationship with such an esteemed professional," commented Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. "Dr. Roseman has a deep, firsthand understanding of the limitations and challenges women face throughout the breast imaging and diagnostic pathway. His decision to deploy the QTI Breast Acoustic CT scanner within his own clinical environment is a strong validation of our mission to provide women with a safer, more comfortable, and clinically meaningful breast imaging solution."

QT Imaging announced the launch of the QTI Imaging-Olea Viewer, developed in collaboration with Olea Medical. "Integrating quantitative, radiation-free QTscan data with mammography, digital breast tomosynthesis, MRI, and ultrasound in a single intuitive platform improves interpretive efficiency, strengthens diagnostic confidence, and supports a more comprehensive multimodality approach to breast evaluation," said Dr. Bilal Malik, Chief Medical Officer of QT Imaging.